Shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) were up 5.4% on Wednesday . The stock traded as high as $16.09 and last traded at $15.96, approximately 164,997 shares traded hands during mid-day trading. A decline of 34% from the average daily volume of 250,346 shares. The stock had previously closed at $15.14.

A number of equities analysts have issued reports on DOVA shares. Wedbush assumed coverage on Dova Pharmaceuticals in a report on Wednesday, May 22nd. They issued an “outperform” rating and a $19.00 price objective for the company. HC Wainwright raised their price objective on Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Zacks Investment Research cut shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 6th. Evercore ISI raised shares of Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 target price on the stock in a research report on Monday, July 1st. Finally, Oppenheimer began coverage on shares of Dova Pharmaceuticals in a research note on Thursday, August 29th. They issued an “outperform” rating and a $30.00 price target for the company. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $24.57.

The company’s fifty day moving average price is $15.36 and its 200-day moving average price is $11.58. The stock has a market capitalization of $443.23 million, a PE ratio of -6.14 and a beta of 2.58. The company has a quick ratio of 5.37, a current ratio of 5.64 and a debt-to-equity ratio of 0.41.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.03). The company had revenue of $3.52 million during the quarter, compared to the consensus estimate of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. Equities research analysts anticipate that Dova Pharmaceuticals Inc will post -2.43 earnings per share for the current year.

In other news, Director Paul B. Manning acquired 28,062 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were bought at an average cost of $15.87 per share, with a total value of $445,343.94. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO David Zaccardelli sold 10,450 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $15.94, for a total transaction of $166,573.00. The disclosure for this sale can be found here. In the last quarter, insiders have acquired 610,916 shares of company stock valued at $8,689,169 and have sold 27,807 shares valued at $422,464. 60.30% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of the business. Quantamental Technologies LLC lifted its stake in shares of Dova Pharmaceuticals by 1,100.0% in the second quarter. Quantamental Technologies LLC now owns 2,400 shares of the company’s stock worth $34,000 after buying an additional 2,200 shares in the last quarter. Capital Investment Advisory Services LLC grew its holdings in shares of Dova Pharmaceuticals by 222.2% during the second quarter. Capital Investment Advisory Services LLC now owns 2,900 shares of the company’s stock valued at $45,000 after buying an additional 2,000 shares during the last quarter. Doyle Wealth Management bought a new stake in shares of Dova Pharmaceuticals during the second quarter valued at approximately $49,000. Jane Street Group LLC bought a new stake in shares of Dova Pharmaceuticals during the second quarter valued at approximately $146,000. Finally, Paloma Partners Management Co bought a new stake in shares of Dova Pharmaceuticals during the second quarter valued at approximately $214,000. 32.18% of the stock is owned by institutional investors and hedge funds.

About Dova Pharmaceuticals (NASDAQ:DOVA)

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Recommended Story: What does relative strength index mean?

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.